



Zentralinstitut für
Seelische Gesundheit

Landesstiftung
des öffentlichen Rechts

Central Institute of Mental Health
Department of Child and Adolescent Psychiatry and Psychotherapy J 5
D-68159 Mannheim
German
[Website](#)

Project leader



**Prof. Dr. Dr. Tobias Banaschewski, MD,
PhD**

Medical Director

Phone +49 (0)621 1703 4502

Fax +49 (0)621 1703 4505

[E-Mail](#)



Prof. Dr. Dr. Ralf W. Dittmann, MD, PhD


Professor of Paediatric Psychopharmacology

Phone +49 (0)621 1703 4941

Fax +49 (0)621 1703 4945

[E-Mail](#)

Project staff




Dr. Nicoletta Adamo, MD

Post Doctoral Fellow

Phone +49 (0)621 1703 4921

Fax n.a.

E-Mail




Dr. Alexander Häge, MD

Phone +49 (0)621 1703 4924

Fax +49 (0)621 1703 4924

E-Mail



Konstantin Mechler

Phone +49 (0)621 1703 4924

Fax +49 (0)621 1703 4945

E-Mail



Ruth Berg, MSc

Study coordinator

Phone +49 (0)621 1703 4941

Fax +49 (0)621 1703 4545

E-Mail

**Dr. Mahmud Ben Dau**

Phone +49 (0)621 1703 4943

Fax +49 (0)621 1703 4545

E-Mail**Institute presentation**

The Central Institute of Mental Health (CIMH) in Mannheim, Germany is an independent public foundation of the State of Baden-Württemberg associated with the University of Heidelberg and is one of Europe's premier research institutions dedicated to mental health. It is dedicated to research in psychiatry, addiction medicine, psychosomatic medicine and psychotherapy, neuroscience, clinical psychology, medical sociology and epidemiology. The Institute has been a Collaborating Centre for Research and Training in Mental Health with the WHO since 1980. The Department of Child and Adolescent Psychiatry and Psychotherapy (CAP), headed by Prof. Tobias Banaschewski, MD, PhD, at the (CIMH), specialises in psychiatric treatment and research in neuropsychiatric disorders (e.g., ADHD, Conduct Disorders, Tourette Syndrome and Autism). Research on efficacy and safety of medication treatment for psychiatric disorders in youths is a main focus of the department's research agenda. In the summer of 2008, the Eli Lilly Endowed Chair for Paediatric Psychopharmacology was established at CAP focusing on clinical research with psychotropic compounds in children and adolescents (Prof Ralf W. Dittmann). The CAP is equipped with 52 inpatient beds distributed in 4 units/wards plus an outpatient facility. The Department's outpatient clinic has about 400 new child and adolescent ADHD patients per year. The clinical and research teams include a total of 18 child and adolescent psychiatrists, 12 senior psychologists and 2 post-doctoral staffs.

Previous experience:

CAP CIMH has been involved in several international collaborations including various multisite medication trials. Prof. Banaschewski has been the principle investigator in several research projects including a current registration trial for a new ADHD compound. He has also been Co-PI on a NIH sponsored project on the genetics of ADHD (International Multisite ADHD Genetics – IMAGE, R01MH62873 to Steve Faraone, P.I.). The CIMH also has extensive experience in the management and implementation of earlier EU FP projects. The CAP CIMH (R.W. Dittmann & T. Banaschewski) is also participating in the Pediatric European Risperidone Study (PERS) which will be funded by FP7 (PI: Jan Buitelaar) and is responsible for the work package ‘Risperidone in Conduct Disorder, acute trial’ (R.W.Dittmann).

Main tasks in the project:

This partner is responsible for the WP06 “Pilot testing of medication in clinical paediatric populations”. In addition, CAP CIMH will participate and contribute to work packages 03 “Human neurochemistry” and 04 “Human neuroimaging”.